The venture was found in Asia in Israel. The main department of described VC is located in the Herzliya.
The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline BIOMx, Orasis Pharmaceuticals, ChemomAb For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel.
Besides them, we counted 3 critical employees of this fund in our database.
The important activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. The top amount of exits for fund were in 2018. Comparing to the other companies, this SBI Japan-Israel Innovation Fund performs on 15 percentage points less the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the SBI Japan-Israel Innovation Fund, startups are often financed by OrbiMed, Takeda Ventures, Seventure Partners. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Takeda Ventures, Seventure Partners. In the next rounds fund is usually obtained by Takeda Ventures, Seventure Partners, RM Global Partners.
Funds with similar focus
|Broad Resources||China, Shanghai|
|Chesapeake Solar||Jessup, Maryland, United States|
|Circle T Partners||New York, New York, United States|
|DCB BANK||India, Maharashtra, Mumbai|
|FGL Holdings||Cayman Islands, Grand Cayman|
|G7 Renewable Energies||Gauteng, NA - South Africa, South Africa|
|Hongdao Dianying Jinrong||China, Hangzhou, Zhejiang|
|Huagen Touzi||China, Guangdong, Guangzhou|
|IMG Investment Partners||-|
|LTS Investments||Brazil, São Paulo, Sao Paulo|
|Maverick Capital||Dallas, Texas, United States|
|Nanjing Guanghe Hudong Touzi||China, Jiangsu, Nanjing|
|Naturals||Chennai, India, Tamil Nadu|
|NTT Data||Japan, Koto|
|Shanghai Wenyuan Touzi Guanli Zhongxin (Youxian Hehuo)||China, Shanghai|
|Shiga Bank||Japan, Otsu, Shiga Prefecture|
|Shin Kong Life Insurance||-|
|$30M||10 Sep 2020||Israel, Tel Aviv District, Israel|
|$19M||11 Mar 2020||Israel, North District|
|$30M||28 May 2019||Israel, Center District|
|$32M||20 Feb 2019||Israel, North District, Israel|
|$17M||08 Jan 2019||Israel, North District|
|$13M||05 Jun 2018||Israel, Tel Aviv District, Israel|
|$10M||04 Dec 2017||Tel Aviv-Yafo, Tel Aviv District, Israel|
|$45M||29 Jun 2017||California, United States|
|$24M||15 May 2017||Israel, North District, Israel|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.